NEC and VAXIMM partner to develop personalized vaccines for cancer

NEC Corporation, a leading firm in network technologies and IT, and VAXIMM AG, a biotech firm focused on the development of oral T-cell immunotherapies, recently announced that both the companies inked a strategic agreement for a clinical trial partnership and an equity investment for the development of innovative personalized neoantigen vaccines for cancer. The terms of this non-exclusive partnership agreement, NEC will be providing funding for the Phase I clinical trial. VAXIMM and NEC will be co-developing personalized vaccines for cancer by using the advanced artificial intelligence (AI) technology of NEC which is used in both of its Neoantigen prediction System and propriety T-cell immunotherapy technology of VAXIMM. Sources informed that the vaccines will be evaluated for several solid tumors in Phase 1 clinical trial. VAXIMM is given the responsibility to conduct the clinical trial that is anticipated to start in 2020.